Expect Hybrid Design Concept/Performance Standards For NGS Regulatory Framework
This article was originally published in The Gray Sheet
Executive Summary
Participants at a recent FDA workshop next-generation sequencing diagnostics mulled the differences between design concept and performance standards to govern development of NGS tests, with many agreeing that a hybrid approach was necessary.
You may also be interested in...
Precision Medicine Plan 'Golden Opportunity' For Device, Diagnostic Firms
A new proposed framework to realize President Obama's Precision Medicine Initiative has significant potential for device and diagnostic companies, according to NIH Director Francis Collins. He says it will give them a "competitive opportunity" to develop cheaper whole genome sequencing tests and open the door to other exciting technologies.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.